Nuon captures $6.05M to develop treatments for autoimmune disease
Nuon Therapeutics, a biotech firm developing medicines to treat autoimmune disease and inflammation, has brought in $6.05 million of a targeted $6.13 million round of equity, according to a filing with the SEC. Based in San Mateo, Calif., the company has representatives from Frazier Healthcare Ventures, Domain Associates and GBS Venture Partners on its board of directors.
Next Story: Zillow launches on Android, as its iPhone app hits 1M downloads
Previous Story: Rummble seeks a location truce as it aggregates check-ins
About the Author, Camille Ricketts
Camille was the lead writer for GreenBeat until August 2010. To reach VentureBeat's current writers, email tips@venturebeat.com.
